Comprehensive Study of the IBMP ELISA IgA/IgM/IgG COVID-19 Kit for SARS-CoV-2 Antibody Detection
Authors:
- Sibelle Botogosque MattarSMSibelle Botogosque Mattar
- Paola Alejandra Fiorani CeledonPCPaola Alejandra Fiorani Celedon
- Leonardo Maia LeonyLLLeonardo Maia Leony
- Larissa de Carvalho Medrado VasconcelosLVLarissa de Carvalho Medrado Vasconcelos
- Daniel Dias SampaioDSDaniel Dias Sampaio
- Fabricio Klerynton MarchiniFMFabricio Klerynton Marchini
- Luis Gustavo MorelloLMLuis Gustavo Morello
- Vanessa Hoysan LinVLVanessa Hoysan Lin
- Sandra CrestaniSCSandra Crestani
- Aquiles Assunção CamelierACAquiles Assunção Camelier
- André Costa MeirelesAMAndré Costa Meireles
- André Luiz Freitas de Oliveira JuniorAJAndré Luiz Freitas de Oliveira Junior
Open Access
- 13 July 2024
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 14 (14) , 1514
Abstract
COVID-19 laboratory diagnosis primarily relies on molecular tests, highly sensitive during early infection stages with high viral loads. As the disease progresses, sensitivity decreases, requiring antibody detection. Since the beginning of the pandemic, serological tests have been developed and made available in Brazil, but their diagnostic performance varies. This study evaluated the IBMP ELISA IgA/IgM/IgG COVID-19 kit performance in detecting SARS-CoV-2 antibodies. A total of 90 samples, including 64 from COVID-19 patients and 26 pre-pandemic donors, were assessed based on time post symptom onset (0–7, 8–14, and 15–21 days). The kit showed 61% sensitivity, 100% specificity, and 72% accuracy overall. Sensitivity varied with time, being 25%, 57%, and 96% for 0–7, 8–14, and 15–21 days, respectively. Similar variations were noted in other commercial tests. The Gold ELISA COVID-19 (IgG/IgM) had sensitivities of 31%, 71%, and 100%, while the Anti-SARS-CoV-2 NCP ELISA (IgG) and Anti-SARS-CoV-2 NCP ELISA (IgM) showed varying sensitivities. The IBMP ELISA kit displayed high diagnostic capability, especially as the disease progressed, complementing COVID-19 diagnosis. Reproducibility assessment revealed minimal systematic and analytical errors. In conclusion, the IBMP ELISA IgA/IgM/IgG COVID-19 kit is a robust tool for detecting anti-SARS-CoV-2 antibodies, increasing in efficacy over the disease course, and minimizing false negatives in RT-PCR COVID-19 diagnosis.Keywords
Funding Information
- Coordination for the Improvement of Higher Education Personnel in Brazil (88887.805768/2023-00, 88887.637869/2021-00, BOL0373/2022, 316456/2021-7, 306448/2023-8)
- Research Support Foundation of the State of Bahia (88887.805768/2023-00, 88887.637869/2021-00, BOL0373/2022, 316456/2021-7, 306448/2023-8)
- National Council for Scientific and Technological Development of Brazil (88887.805768/2023-00, 88887.637869/2021-00, BOL0373/2022, 316456/2021-7, 306448/2023-8)
This publication has 44 references indexed in Scilit:
- Antibody tests for identification of current and past infection with SARS-CoV-2Cochrane Database of Systematic Reviews, 2022
- Virus variant–specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022Clinical Microbiology and Infection, 2022
- How to interpret and use COVID-19 serology and immunology testsClinical Microbiology and Infection, 2021
- Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infectionCochrane Database of Systematic Reviews, 2021
- Comparison of six commercially available SARS-CoV-2 antibody assays—Choice of assay depends on intended useInternational Journal of Infectious Diseases, 2021
- Evaluation of diagnostic accuracy of 10 serological assays for detection of SARS-CoV-2 antibodiesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human MilkiScience, 2020
- Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAsClinical Microbiology and Infection, 2020
- Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patientsJournal of Infection, 2020
- Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosisJournal of Medical Virology, 2020